Assessing the Impact of Efalizumab on Nail, Scalp and Palmoplantar Psoriasis and on Quality of Life: Results from a Multicentre, Open-label, Phase IIIb/IV Trial

This post-approval, open-label trial (n = 1266) assessed the efficacy of efalizumab, administered in accordance with the European label at that time, in patients with concomitant nail, scalp or palmoplantar psoriasis. Patients received subcutaneous efalizumab 1.0 mg/kg weekly for up to 20 weeks. By...

Descripción completa

Detalles Bibliográficos
Autores principales: Katsambas, Andreas, Peris, Ketty, Vena, Gino, Freidmann, Peter, Wozel, Gottfried, Daudén, Esteban, Licu, Daiana, Placchi, Mauro, De La Brassinne, Michel
Formato: Texto
Lenguaje:English
Publicado: Blackwell Publishing Inc 2009
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2805869/
https://www.ncbi.nlm.nih.gov/pubmed/20098509
http://dx.doi.org/10.1111/j.1753-5174.2009.00023.x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2805869/
https://www.ncbi.nlm.nih.gov/pubmed/20098509
http://dx.doi.org/10.1111/j.1753-5174.2009.00023.x

Ejemplares similares